Praxis Precision Medicines, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Praxis Precision Medicines, Inc. - overview
Established
2015
Location
Cambridge, MA, US
Primary Industry
Biotechnology
About
Founded in 2015 by co-founders David Goldstein, Kiran Reddy, and Steven Petrou and based in Massachusetts, US, Praxis Precision Medicines, Inc. researches and develops therapies for neurological disorders. The company utilizes genome sequencing to determine parts of the brain that light up with regard to diseases such as epilepsy, mood disorders, pain syndromes, and movement disorders. In March 2024, Praxis Precision Medicines, Inc.
raised USD 187. 5 million in a private placement, selling 3. 31 million shares at USD 56. 5 apiece on the Nasdaq Global Select Market.
In addition, underwriters were granted a 30-day option to purchase up to 530,973 additional shares. The company product pipeline includes several drug candidates in different stages of clinical trials, including PRAX-944 for essential tremor and PRAX-628 for specific types of epilepsy. The cerebrum platform utilizes genetic insights to identify potential drug targets for CNS disorders characterized by imbalances in neuronal excitation and inhibition. Additionally, the solidus platform utilizes antisense oligonucleotide (ASO) technology to regulate the expression of genes linked to CNS disorders.
Current Investors
Novo Holdings, Clarus Ventures, Eventide Asset Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.praxismedicines.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.